CE Courses



Companies that enroll in the 2016 CE Program will receive the following courses:


Anemia: RED FLAGS and Critical Issues
Underwriting guidelines often understate the true significance of anemia in various contexts. This course will cover insurability issues in iron, vitamin B-12 and folate deficiencies; anemia as a major issue in cardiovascular disease and the insidious implications of nonspecific low hemoglobin (anemia) for frailty, cognitive dysfunction and mortality in the elderly. We will also discuss the pros and cons of screening applicants with hemoglobin.


Depression and Bipolar Disorder: RED FLAGS and Critical Issues
Underwriters see many cases of acute/chronic unipolar major and minor depression, and bipolar spectrum disorders. Using the most recent studies, we will delineate depression/bipolar subtypes, and the insurability impact of symptoms, comorbidities, treatment methods, complications and mortality/morbidity.


Chronic Hepatitis C (HCV): RED FLAGS and Critical Issues
Chronic HCV is the #1 cause of cirrhosis, liver cancer and liver transplantation. Mortality from HCV is expected to increase steadily well into the 2200s. We will dissect all relevant aspects of chronic hepatitis C including implications of test and biopsy findings, extrahepatic manifestations, complications, new forms of treatment; plus identify and explain RED FLAG mortality factors.


Diabetic Kidney, Nervous System, Eye and Foot Diseases: RED FLAGS and Critical Issues
When we asked enrollees to choose this year’s curriculum, this course was among those most highly requested…which is understandable considering the protean insurability concerns in these common microangiopathies. We will review and discuss the latest evidence for their manifestations, treatment, consequences and impact on diabetic outcomes.


Lipid Disorders: RED FLAGS and Critical Issues Parts 1 & 2
Lipid markers play a huge role in CV risk analysis and some are routinely used to screen applicants. There have been major developments here that are not reflected in our current practices including novel new insights into HDL-C and triglycerides, non-HDL-C (a superior new marker now done routinely by clinicians), the best approach to evaluating lipid Rx, underwriting implications of statin use, and much more.


Sleep Apnea and other Sleep-Related Disorders: RED FLAGS and Critical Issues Parts 1 & 2
Sleep apnea, chronic insomnia and its Rx, restless leg syndrome, sleep duration and other sleep-related matters have major mortality and morbidity risk issues. We will cover all aspects of sleep related to insurability with special emphasis on the latest developments in our expanding knowledge of sleep apnea.


Suicidal and Self-Harm Behaviors: RED FLAGS and Critical Issues
The incidence of suicide is increasing and it is a major issue for mortality at all ages, including one of the leadings causes of death under age 40. Despite this, little new has been published for underwriters. Self-harm behaviors are also coming into focus as markers for other high-risk behaviors. This course will address risk factors and oft-elusive clues to these behaviors, relationships with comorbidities and mortality/morbidity outcomes in all age groupings.


Advanced Psychiatric Case Clinic: The Art of Underwriting
We are doing one case clinic in 2016. It centers on psychiatric disorders, melded together with other widely ranging medical and nonmedical insurability issues to create 10 challenging multifactorial cases. Each is outlined for the participant to dissect and analyze and then to match up with our assessment of what matters and why, how aspects interconnect and then come together to precisely define the whole risk.


Opioid Use, Abuse and Dependance
Opioid-related mortality and morbidity has become a prominent issue in recent years. This course will address all aspects of opioids, including prescription uses, risk factors for abuse/dependance, association with heroin use, and red flags for mortality and morbidity.


Drug Abuse 2016
This course will dissect all insurability issues in a wide range of illicit drugs, including marijuana, cocaine, anabolic steroids, psychedelics, and two prominent classes of designer drugs (synthetic cannabinoids and cathinone hallucinogens). Underwriters will learn all of the latest developments essential to assessing the implications of using these drugs.